Repligen Corp. (RGEN) Business Model Gives Stock Investors Rapid Returns
Many stock investors worry about the Biotechnology & Drugs Industry. Scientists start companies and spend years in cash-loss research. Clinical trials seem to take forever, and that is without marketing investments to get doctors to prescribe. Profits are rare in this part of the otherwise rich Healthcare Sector. High risks and long gestation periods appear to be downsides of an otherwise interesting industry. Here is a stock with a difference. It has a Net Profit Margin on a Trailing Twelve Months basis of more than 200%. Return on Average Assets has topped 80% during this period. What can account for…